EC Number   |
Inhibitors |
Structure |
|---|
   3.4.21.20 | 11-oxo-beta-boswellic acid |
0.01 mM, 30% cathepsin G activity compared to control |
   |
| 3.4.21.20 | 2-(N-methyl)benzylamino-3,1-benzoxazin-4-one |
strongest inhibition |
|
| 3.4.21.20 | 2-amino-3,1-benzoxazin-4-ones |
non-covalent complex formation, hydrophobic and basic residues at position 2, kinetics of acylation and desacylation, binding at the enzyme's active site |
|
| 3.4.21.20 | 3-O-acetyl-11-oxo-beta-boswellic acid |
0.01 mM, 15% cathepsin G activity compared to control |
|
| 3.4.21.20 | 3-O-acetyl-beta-boswellic acid |
0.01 mM, 5% cathepsin G activity compared to control |
|
| 3.4.21.20 | 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride |
- |
|
| 3.4.21.20 | 6-((1'R)-camphanyl)amino-2-[(ethylsulfonyl)oxy]-1H-isoindole-1,3-dione |
- |
|
| 3.4.21.20 | 6-((1'R,2'S,5'R)-menthyloxycarbonyl)amino-2-[(ethylsulfonyl)oxy]-1H-isoindole-1,3-dione |
- |
|
| 3.4.21.20 | 6-((1'S)-camphanyl)amino-2-[(ethylsulfonyl)oxy]-1H-isoindole-1,3-dione |
selective inhibition |
|
| 3.4.21.20 | 6-((1'S,2'R,5'S)-menthyloxycarbonyl)amino-2-[(ethylsulfonyl)oxy]-1H-isoindole-1,3-dione |
- |
|
